Novel strategies in the treatment of acute lymphoblastic leukaemia
- PMID: 35358432
- DOI: 10.1016/S2352-3026(22)00054-0
Novel strategies in the treatment of acute lymphoblastic leukaemia
Conflict of interest statement
I have received research support from Amgen, OBI, Pfizer, Immunogen, Seattle Genetics, Macrogenics, Kite, Servier, and Glycomimetics; and have been on advisory boards for or received honoraria from Amgen, Kura, Kite, Glycomimetics, Beam, Pfizer, Jazz, and Taiho.
MeSH terms
LinkOut - more resources
Full Text Sources
